Library

Language
Preferred search index
Number of Hits per Page
Default Sort Criterion
Default Sort Ordering
Size of Search History
Default Email Address
Default Export Format
Default Export Encoding
Facet list arrangement
Maximum number of values per filter
Auto Completion
Feed Format
Maximum Number of Items per Feed
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    ISSN: 1433-0393
    Keywords: SchlüsselwörterZervixkarzinom ; Strahlentherapie ; Kombinationstherapie ; 13cis-Retinsäure ; Interferon ; Key wordsCarcinoma of the cervix ; Radiotherapy ; Combination therapy ; 13-cis-retinoic acid ; Interferon
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Summary Although carcinoma screening is now widely available, cervical carcinoma is still the fourth most common tumour among women in the USA and in the western industrialized nations. There are about 14,000 new cases every year. In underdeveloped countries carcinoma of the cervix is widespread and often the most frequent tumour[18]. Besides primarily surgical treatment radiotherapy is the main curative treatment modality, the 5-year survival rates after therapy being around 90% for stage I disease and 7% for stage IV (FIGO Annual Report). It therefore seems desirable to look for therapeutic concepts, with the aim of improving the present results further by means of new combinations of irradiation with a systemic therapy.
    Notes: Zusammenfassung Trotz der weit verbreiteten Karzinomvorsorge stellt das Zervixkarzinom in den USA und den westlichen Industrienationen immer noch den vierthäufigsten Tumor bei Frauen dar. Die Anzahl von Neuerkrankungen beträgt ca. 14 000 neue Fälle pro Jahr. In unterentwickelten Ländern ist das Zervixkarzinom weit verbreitet und oft der häufigste Tumor[18]. Neben dem primär chirurgischen Vorgehen stellt die Strahlentherapie die wesentliche kurative Behandlungsmodalität dar, wobei die 5-Jahres-Überlebensraten nach Therapie bei 90% für das Stadium I und 7% für das Stadium IV liegen (FIGO Annual Report). Es erscheint daher sinnvoll, nach therapeutischen Konzeptionen zu suchen, um durch neue Kombinationen der Bestrahlung mit einer System-Therapie die gegenwärtigen Ergebnisse weiter zu verbessern.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    ISSN: 0942-0940
    Keywords: Pituitary tumour recurrence ; clinical symptoms ; CT-investigation ; recurrence rate ; prolactin level examination ; combined modality of surgical and radiotherapy
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary The tumour recurrence rate of 210 patients with operated hypophysomas were investigated. Depending on the surgicaal approach, total or subtotal extirpation of the adenomas, the recurrence rates varied from 10,4 to 35%. 33 patients with pituitary tumour recurrences were followed up over a period of 20 years. Clinical symptoms CT-results at relapse are represented. Serum prolactin level (PRL) was determined before and after surgical and radiotherapy of PRL-producing adenomas. In these cases PRL can be accepted as a tumour marker. 13 patients with relapsed hypophysomas received local irradiation (5.7 MeV linear accelerator) after recurrence operation. An individual comparison in the same patient between surgical therapy alone and combined surgical and radiotherapy was possible. Based on the obtained experience with this combined treatment a therapy scheme using combined surgery and radiotherapy in pituitary tumours is suggested.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...